by OncoAdmin | Nov 7, 2022 | Press Releases Eng
PRESS RELEASE Oncorena presents at BioStock Life Science Fall Summit in Lund LUND, SWEDEN, November 7, 2022 – Oncorena announces that the company will participate at the BioStock Life Science Fall Summit in Lund, Sweden, on November 29 – 30. CEO and Chief Scientific...
by OncoAdmin | Sep 29, 2022 | Press Releases Eng
PRESS RELEASE Oncorena expands its management team and strengthens its focus on the company’s initiated clinical Phase I-II study with orellanine LUND, SWEDEN, September 29, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment...
by OncoAdmin | Jun 20, 2022 | Press Releases Eng
PRESS RELEASE Börje Haraldsson appointed CEO of Oncorena AB LUND, SWEDEN, June 20, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that the Board of Directors of...
by OncoAdmin | May 23, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Presents Two Abstracts on Orellanine at the Nordic Society of Nephrology LUND, SWEDEN, May 23, 2022 – Oncorena presented two abstracts on orellanine at the Nordic Society of Nephrology, in Odense, Denmark on May 4-7. Oncorena is developing...
by OncoAdmin | Feb 2, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Strengthens its Management Team and Appoints Professor Börje Haraldsson as Chief Scientific Officer LUND, SWEDEN, February 2, 2022 – Oncorena, developing a potential breakthrough therapy for advanced renal cancer, announced today that...
by OncoAdmin | Feb 1, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden LUND, SWEDEN, February 1, 2022 – Oncorena today announced the initiation of the Phase I-II clinical...
